Related Experiment Video

Updated: Jun 5, 2025

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
18:46

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

13.3K

Better blood pressure control with the nanoformulation of antihypertensive drugs

Steven G Chrysant1

  • 1Department of Cardiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Expert Review of Cardiovascular Therapy
|December 5, 2024
PubMed

Insights

Nanotechnology offers improved hypertension treatment by enhancing drug delivery and stability. Nanoformulations of drugs and genes show promise for better blood pressure control, addressing limitations of current therapies.

Area of Science:

  • Nanomedicine
  • Cardiovascular Pharmacology
  • Drug Delivery Systems

Background:

  • Hypertension is a prevalent global health issue and a major risk factor for severe cardiovascular diseases.
  • Poor blood pressure control affects a significant portion of the population, particularly in developing countries.
  • Existing antihypertensive drug formulations face challenges including suboptimal drug concentration, stability, solubility, and bioavailability.

Purpose of the Study:

  • To review recent advancements in nanomedicine for hypertension treatment.
  • To explore the efficacy of nanoformulated drugs and genes in managing hypertension.
  • To assess the benefits of nanotechnology in overcoming limitations of conventional antihypertensive therapies.

Main Methods:

  • A comprehensive literature search was conducted on Medline, covering publications from 2017 to 2024.
  • 36 relevant research papers focusing on nanotechnology in hypertension treatment were selected for analysis.
  • The review synthesized findings on nanoformulations of both drugs and therapeutic genes.

Main Results:

  • Nanoformulations enhance drug concentration, stability, solubility, and oral bioavailability of antihypertensive agents.
  • Nanotechnology can improve pharmacokinetic and pharmacodynamic profiles and reduce adverse effects of hypertension medications.
  • Preliminary studies indicate that nanoformulated genes are effective for treating hypertension and cardiovascular diseases, though further research is necessary.

Conclusions:

  • Nanotechnology presents a promising approach to improve the efficacy and safety of hypertension management.
  • Nanoformulations offer significant advantages over conventional drug delivery systems for antihypertensive therapies.
  • Further research into gene nanoformulation is warranted to fully realize its therapeutic potential in cardiovascular medicine.
Abstract

Keywords:
Cardiovascular diseaseCardiovascular diseaseNanoformulationantihypertensive drugscontrolhypertension

More Related Videos

Formulation and Characterization of Bioactive Agent Containing Nanodisks07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

1.0K
Flash NanoPrecipitation for the Encapsulation of Hydrophobic and Hydrophilic Compounds in Polymeric Nanoparticles10:12

Flash NanoPrecipitation for the Encapsulation of Hydrophobic and Hydrophilic Compounds in Polymeric Nanoparticles

Published on: January 7, 2019

21.9K

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
618
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
476
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
477
Blood Pressure01:30

Blood Pressure

Blood pressure (BP) is the pressure or force of blood exerted on the artery's walls as it circulates through the body. It is essential for maintaining blood flow throughout the body.
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
998
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
581
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K